Importer of Controlled Substances Application: Galephar Pharmaceutical Research, Inc., 41065 [2020-14614]
Download as PDF
<![CDATA[
41065
Federal Register / Vol. 85, No. 131 / Wednesday, July 8, 2020 / Notices
personnel will sign appropriate
nondisclosure agreements.
Controlled
substance
Authority: These investigations are being
conducted under authority of title VII of the
Tariff Act of 1930; this notice is published
pursuant to section 207.12 of the
Commission’s rules.
By order of the Commission.
Issued: July 1, 2020.
Lisa Barton,
Secretary to the Commission.
Drug code
Psilocyn ...................
7438
Schedule
I
The institute plans to import the
listed controlled substances for
potential formulation development for
substances to be used in institutesponsored research.
[FR Doc. 2020–14625 Filed 7–7–20; 8:45 am]
BILLING CODE 7020–02–P
[FR Doc. 2020–14624 Filed 7–7–20; 8:45 am]
Drug Enforcement Administration
[Docket No. DEA–680]
ACTION:
Importer of Controlled Substances
Application: Galephar Pharmaceutical
Research, Inc.
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before August 7, 2020. Such persons
may also file a written request for a
hearing on the application on or before
August 7, 2020.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for a hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on May 21, 2020, Usona
Institute, 2780 Woods Hollow Road,
Room 2412, Fitchburg, Wisconsin
53711–5370, applied to be registered as
an importer of the following basic
class(es) of controlled substances:
jbell on DSKJLSW7X2PROD with NOTICES
DATES:
Controlled
substance
5-Methoxy-N-Ndimethyltryptamine.
Dimethyltryptamine ..
Psilocybin ................
VerDate Sep<11>2014
Drug code
Schedule
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before August 7, 2020. Such persons
may also file a written request for a
hearing on the application on or before
August 7, 2020.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on June 22, 2020, Galephar
Pharmaceutical Research, Inc., 100 Carr
198 Industrial Park, Juncos, Puerto Rico
00777–3873, applied to be registered as
an importer of the following basic
class(es) of a controlled substance:
DATES:
7431
I
Controlled
substance
7435
7437
I
I
Hydromorphone .......
17:17 Jul 07, 2020
Jkt 250001
PO 00000
Frm 00104
Fmt 4703
[Docket No. DEA–681]
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before August 7, 2020. Such persons
may also file a written request for a
hearing on the application on or before
August 7, 2020.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on May 28, 2020,
Xcelience, 4901 West Grace Street,
Tampa, Florida 33607–3805, applied to
be registered as an Importer of the
following basic class(es) of controlled
substances:
DATES:
[Docket No. DEA–679]
Notice of application.
BILLING CODE P
Importer of Controlled Substances
Application: Xcelience
DEPARTMENT OF JUSTICE
Importer of Controlled Substances
Application: Usona Institute
[FR Doc. 2020–14614 Filed 7–7–20; 8:45 am]
Drug Enforcement Administration
BILLING CODE P
Drug Enforcement Administration
William T. McDermott,
Assistant Administrator.
DEPARTMENT OF JUSTICE
William T. McDermott,
Assistant Administrator.
DEPARTMENT OF JUSTICE
The company plans to import the
listed controlled substance in finished
dosage form for analytical purpose only.
Drug code
9150
Sfmt 4703
Schedule
II
Controlled
substance
Psilocybin ................
Amphetamine ..........
Drug code
7437
1100
Schedule
I
II
The company plans to import drug
code 7437 (Psilocybin), as bulk and drug
code 1100 (Amphetamine), as finished
dosage form for clinical trials, research,
and analytical purposes. No other
activity for drug code 1100 is authorized
for this registration. Approval of permit
E:\FR\FM\08JYN1.SGM
08JYN1
]]>Agencies
[Federal Register Volume 85, Number 131 (Wednesday, July 8, 2020)]
[Notices]
[Page 41065]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-14614]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-679]
Importer of Controlled Substances Application: Galephar
Pharmaceutical Research, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before August 7, 2020.
Such persons may also file a written request for a hearing on the
application on or before August 7, 2020.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for a hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on June 22, 2020, Galephar Pharmaceutical Research,
Inc., 100 Carr 198 Industrial Park, Juncos, Puerto Rico 00777-3873,
applied to be registered as an importer of the following basic
class(es) of a controlled substance:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Hydromorphone......................... 9150 II
------------------------------------------------------------------------
The company plans to import the listed controlled substance in
finished dosage form for analytical purpose only.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-14614 Filed 7-7-20; 8:45 am]
BILLING CODE P
